Prescribing Patterns of Evolocumab and Alirocumab in Patients With Familial Hypercholesterolemia: A Cross-Sectional Study Using the National Ambulatory Medical Care Survey, 2018–2019
PCSK9 inhibitor use in FH patients during U.S. ambulatory visits was rare, highlighting a persistent gap between evidence-based guidelines and clinical practice. Broader adoption strategies are needed to optimize lipid management and reduce cardiovascular risk in FH.
Authors
- Ryda D. Rose
- Efeturi Okorigba
- Emmanuel Adu
- Nneka Muoghalu
- Kehinde H Jinadu
- Akinyemi Akinwumiju
Institutions
- West Virginia University (US)
- Liverpool School of Tropical Medicine (GB)
- University College Hospital, Ibadan (NG)
- St John of God Hospital (AU)
- Kingston Hospital (GB)
- Center for Psychiatry and Behavioral Medicine (US)
- Leeds Dental Hospital (GB)
Publication Details
- Journal
- Cureus
- Published
- 2025-10-02
- DOI
- https://doi.org/10.7759/cureus.93695
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00